Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) Announce New Indication for VivaGel(R):...

Wednesday July 9 6:37 PM Melbourne, Australia, July 9, 2008 - (ABN Newswire) - Starpharma Holdings Limited (ASX: SPL.AX)(PINK:SPHRY) today announced that it will add the treatment of bacterial vaginosis (BV) to the development program for its vaginal microbicide VivaGel(R). This is the first application of VivaGel(R) as a treatment. The existing applications are for prevention of infection by the sexually transmitted viruses that cause AIDS (HIV), genital herpes (HSV) and genital warts (HPV), or contraception. Bacterial Vaginosis is characterised by an imbalance between the naturally occurring vaginal lactobacilli and disease-causing bacteria. It is a major cause of vaginal infection and is particularly prevalent in the US, where it is reported to affect 29% of women.** The condition is implicated in pelvic inflammatory... [read full story]